camphor ketal | 10395-50-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: camphor ketal
• 英文别名: 2,2-dimethoxy-1,7,7-trimethylbicyclo<2.2.1>heptane；camphor dimethyl acetal；(+/-)-Campher-dimethylketal；2,2-Dimethoxy-1,7,7-trimethyl bicyclo-[2-2-1]heptane；1,7,7-Trimethyl-2-norbornanone dimethyl ketal；2,2-dimethoxy-1,7,7-trimethylbicyclo[2.2.1]heptane
• CAS: 10395-50-3
• 化学式: C₁₂H₂₂O₂
• 分子量: 198.305
• InChiKey: RRCYFCPKYNYACP-UHFFFAOYSA-N

物化性质

• 沸点：
  213.7±13.0 °C(Predicted)
• 密度：
  0.97±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  camphor ketal 在 三氟化硼乙醚 作用下， 生成 2-Methoxy-1,7,7-trimethyl-bicycl<2.2.1>hept-2-yl-fluoroborat
  参考文献：
  名称：

  The Rates of Methoxyl Exchange of Camphor and Norcamphor Dimethyl Ketals in Methanol-d₄

  摘要：

  DOI：

  10.1021/ja00973a030
• 作为产物：
  描述：

  樟脑 、 原甲酸三甲酯 在 对甲苯磺酸 作用下， 以 甲醇 为溶剂， 生成 camphor ketal
  参考文献：
  名称：

  Thermochemical studies of carbonyl reactions. 4. Enthalpies of hydrolysis of norbornyl ketals

  摘要：

  DOI：

  10.1021/jo00289a051

文献信息

• Synthesis of non-hydrolysable mimics of glycosylphosphatidylinositol (GPI) anchors
  作者：Mahipal Yadav、Riya Raghupathy、Varma Saikam、Saidulu Dara、Parvinder Pal Singh、Sanghapal D. Sawant、Satyajit Mayor、Ram A. Vishwakarma

  DOI：10.1039/c3ob42116c

  日期：——

  Synthesis of first generation non-hydrolysable C-phosphonate GPI analogs, viz., 6-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-D-myo-inositol-1-O-(sn-3,4-bis(palmitoyloxy)butyl-1-phosphonate) 23a and 6-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-D-myo-inositol-1-O-(sn-2,3-bis(palmitoyloxy)propyl-1-phosphonate) 23b, is reported. The target compounds were synthesized by the coupling of α-pseudodisaccharide 21 with

  第一代不可水解的C-GPI膦酸酯类似物，合成v IZ，6-。ø - （2-氨基-2-脱氧-3-α- d吡喃葡萄糖基） - d -肌醇肌醇-1- Ö - （SN - 3,4-双（棕榈酰氧基）丁基-1-膦酸盐）23A和6- ø - （2-氨基-2-脱氧-3-α- d吡喃葡萄糖基） - d -肌醇肌醇-1- ö - （SN -2据报道，（3-双（棕榈酰氧基）丙基-1-膦酸酯）23b。通过将α-假二糖21与膦酸偶联来合成目标化合物分别以定量收率得到18a和18b，然后脱保护。这些合成的C-膦酸酯GPI探针对磷脂酰肌醇特异性磷脂酶C（PI-PLC）具有抗性，并且还显示出对酶活性的中等抑制作用。
• [EN] CAMPHANYLIDENE AND PHENYLALKYL INOSITOL POLYPHOSPHATE COMPOUNDS, COMPOSITIONS, AND METHODS OF THEIR USE<br/>[FR] COMPOSES DE CAMPHANYLIDENE ET POLYPHOSPHATES D'INOSITOL PHENYLALKYLE, COMPOSITIONS ET LEURS PROCEDES D'UTILISATION
  申请人：INOLOGIC INC

  公开号：WO2004087721A1

  公开（公告）日：2004-10-14

  This invention relates to new camphanylidene and phenyl alkyl inositol polyphosphate derivatives that inhibit the absorption of sodium ions in epithelial cells and regulate inducible nitric oxide synthase (iNOS) in macrophages. The invention provides methods for inhibiting sodium ion absorption by epithelial cells and/or regulating inducible nitric oxide synthase (iNOS) in macrophages, by treating epithelial cells or administering to a patient in need of such treatment a therapeutically effective amount of camphanylidene and/or phenyl alkyl inositol polyphosphate compound. Representative camphanylidene and phenyl alkyl inositol polyphosphate compounds include, for example, 1,2-camphanylidene-myo-inositol 3,4,5,6-tetrakisphosphate octakis (propionoxymethyl) ester (INO-4996), 2,3-camphanylidene-myo-inositol 1,4,5,6­-tetrakisphosphate octakis (propionoxymethyl) ester (INO-4984) and 2-O-butyryl-1-O-(3-­phenylpropyl)-myo-inositol 3,4,5,6-tetrakisphosphate octakis (propionoxymethyl) ester (INO-4997).

  这项发明涉及新的松节醇亚烯基和苯基烷基肌醇多磷酸衍生物，能够抑制上皮细胞中钠离子的吸收并调节巨噬细胞中的诱导型一氧化氮合酶（iNOS）。该发明提供了通过治疗上皮细胞或向需要此类治疗的患者施用松节醇亚烯基和/或苯基烷基肌醇多磷酸化合物的治疗方法，以抑制上皮细胞中的钠离子吸收和/或调节巨噬细胞中的诱导型一氧化氮合酶（iNOS）。代表性的松节醇亚烯基和苯基烷基肌醇多磷酸化合物包括，例如，1,2-松节醇亚烯基-肌醇3,4,5,6-四磷酸八(丙酰氧甲基)酯（INO-4996）、2,3-松节醇亚烯基-肌醇1,4,5,6-四磷酸八(丙酰氧甲基)酯（INO-4984）和2-O-丁酰基-1-O-(3-苯基丙基)-肌醇3,4,5,6-四磷酸八(丙酰氧甲基)酯（INO-4997）。
• Photochemical Acetalization of Carbonyl Compounds in Protic Media Using an in Situ Generated Photocatalyst
  作者：H. J. Peter de Lijser、Natalie Ann Rangel

  DOI：10.1021/jo0485886

  日期：2004.11.1

  Carbonyl compounds are conveniently converted into their corresponding dimethyl acetals in good yields and short reaction times by means of a photochemical reaction in methanol with a catalytic amount of chloranil (2,3,5,6-tetrachloro-1,4-benzoquinone, CA) as the sensitizer. Using aldehydes gives better results than using ketones, which also tend to form enol ethers as side products. These results

  羰基化合物可通过在甲醇中与催化量的邻苯二甲腈（2,3,5,6-四氯-1,4-苯醌，CA）进行光化学反应，以高收率和较短的反应时间方便地转化为相应的二甲基乙缩醛。作为敏化剂。使用醛比使用酮产生更好的结果，酮也倾向于形成烯醇醚作为副产物。这些结果类似于简单的酸催化的缩醛化反应，表明光化学产生的酸的参与。根据稳态和激光闪光光解数据，提出该反应涉及通过CA与溶剂反应原位生成光催化剂（2,3,5,6-四氯-1,4-氢醌，TCHQ） 。缩醛化过程是由TCHQ的电离引发的，然后质子损失到溶剂或羰基中，从而开始催化反应。光催化剂通过歧化反应再生。
• SYNTHETIC ANALOGUES OF PHOSPHATIDYL-MYO-INOSITOL MANNOSIDES WITH AN INHIBITORY ACTIVITY OF THE INFLAMMATORY RESPONSE
  申请人：Quesniaux Fyffel Valérie

  公开号：US20110224162A1

  公开（公告）日：2011-09-15

  The present invention relates to novel synthetic analogues of phosphatidyl-myo-inositol mannosides (hereinafter referred to as PIMs) of general formula (I): or a pharmaceutically acceptable salt thereof, to the method for preparing same and to the use thereof in the prevention or treatment of a disease associated with the overexpression of cytokines or of chemokines, in particular of TNF and/or of IL-12. The invention also relates to a pharmaceutical composition comprising at least one synthetic derivative of PIM.

  本发明涉及磷脂酰肌醇甘露聚糖的新型合成类似物（以下简称为PIMs），其一般公式为（I）或其药学上可接受的盐，以及其制备方法和在预防或治疗与细胞因子或趋化因子过表达相关的疾病中的应用，特别是TNF和/或IL-12。该发明还涉及包含至少一种PIM的合成衍生物的药物组合物。
• PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES
  申请人：Dave Mayank Ghanshyambhai

  公开号：US20120202988A1

  公开（公告）日：2012-08-09

  The invention relates to processes for the preparation of compound of CCI-779 having the Formula (I), which is useful as an antineoplastic agent. The invention further relates to certain novel intermediates useful in the preparation of compound of CCI-779 and processes for their preparation. The invention also relates to pharmaceutical compositions that include the compound of CCI-779, prepared according to the processes disclosed herein.

  该发明涉及制备具有化学式（I）的CCI-779化合物的过程，该化合物可作为抗肿瘤药物。该发明还涉及在制备CCI-779化合物过程中有用的某些新型中间体以及它们的制备过程。该发明还涉及包含根据本文披露的方法制备的CCI-779化合物的药物组合物。